Targeting the GRP78 Pathway for Cancer Therapy

Guanhua Lu; Hui Luo; Xiao Zhu

doi:10.3389/fmed.2020.00351

Targeting the GRP78 Pathway for Cancer Therapy

Front Med (Lausanne). 2020 Jul 30:7:351. doi: 10.3389/fmed.2020.00351. eCollection 2020.

Authors

Guanhua Lu¹, Hui Luo^{1

2

3

4}, Xiao Zhu^{1

2

3

4}

Affiliations

¹ Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
² The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China.
³ Southern Marine Science and Engineering Guangdong Laboratory, Zhanjiang, China.
⁴ The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China.

Abstract

The 78-kDa glucose-regulated protein (GRP78) plays an important part in maintaining protein stability, regulating protein folding, and inducing apoptosis autophagy, which is considered as a powerful protein. Meanwhile, it also plays a role in ensuring the normal function of organs. In recent years, more and more researches have been carried out on the targeted therapy of GRP78, mainly focusing on its relevant role in tumor and its role as a major modulator and modulator of subordinate pathways. The ability of GRP78 to respond to endoplasmic reticulum stress (ERS) determines whether tumor cells survive and whether the changes in expression level of GRP78 regulated by endoplasmic reticulum (ER) caused by various factors will directly or indirectly affect cell proliferation, apoptosis, and injury, or reduce the body's defense ability, or have protective effects on various organs.

Keywords: GRP78; apoptosis; autophagy; endoplasmic reticulum stress; tumor-targeted therapy.

Publication types

Review